Satavaptan OverviewSatavaptan (INN; developmental code name SR121463, former tentative brand name Aquilda) is a vasopressin-2 receptor antagonist which was investigation by Sanofi-Aventis and was under development for the treatment of hyponatremia. It was also being studied for the treatment of ascites. Development was discontinued in 2009. References ^ Soupart A, Gross P, Legros JJ, et al. (November 2006). "Successful long-term treatment of hyponat...
Read more Satavaptan Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Satavaptan
Recent Satavaptan Forums:Be the first to start a discussion about this drug.
Other drugs which contain Satavaptan or a similar ingredient: (1 result)
- AQUILDA Satavaptan